COLL - Collegium Pharmaceutical GAAP EPS of $0.01 beats by $0.15 revenue of $127M beats by $2.64M
- Collegium Pharmaceutical press release ( NASDAQ: COLL ): Q3 GAAP EPS of $0.01 beats by $0.15 .
- Revenue of $127M (+61.1% Y/Y) beats by $2.64M .
- Updated Full Year 2022 Guidance : Total Product Revenues seen at $455M to $465M, prior outlook $450M to $465M; adj EBITDA expected between $250M-255M.
For further details see:
Collegium Pharmaceutical GAAP EPS of $0.01 beats by $0.15, revenue of $127M beats by $2.64M